Revance Therapeutics Inc RVNC

Healthcare

Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to commercialize DAXXIFY in China. Its product/product candidate includes DAXXIFY for glabellar lines indication; DAXXIFY for cervical dystonia indication; RHA Redensity for perioral rhytids indication; RHA 2/ RHA 3/ RHA 4 for facial wrinkles and folds (such as nasolabial folds) indication; DAXXIFY for forehead lines, lateral canthal lines, upper facial lines indication; DAXXIFY for upper limb spasticity indication, and onabotulinumtoxinA biosimilar. The Company has exclusive right to import, market, promote, sell and distribute Teoxane's line of Resilient Hyaluronic Acid dermal fillers.

NDAQ:RVNC - Post by User

Revance Therapeutics Inc

Bullboard Posts

Next >>

Post by whytestockson Mar 04, 2024 6:00pm

57 Views

Post# 35914477

Revance Announces Pricing of $100.0 Million Public Offering

Just In: $RVNC Revance Announces Pricing of $100.0 Million Public Offering of Common StockRevance Therapeutics, Inc. (Nasdaq: RVNC) (“Revance” or the “Company”) today announced the pricing of an underwritten public offering of 16,000,000 shares of its common stock. The shares of common stock are being offered at a public offering price of $6.25 per share. T...RVNC - Revance Announces Pricing of $100.0 Million Public Offering of Common Stock

Bullboard Posts

Next >>

Osisko Development receives permits for Cariboo Gold Project